Pharmaceutical compositions and methods
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
1. A method for treating cancer in a patient comprising administering to the patient an effective amount of:
a) a tyrosine hydroxylase inhibitor that is one or more of methyl (2R)-2-amino-3-(2-chloro-4-hydroxyphenyl) propanoate, D-tyrosine ethyl ester hydrochloride, methyl (2R)-2-amino-3-(2,6-dichloro-3,4-dimethoxyphenyl) propanoate H-D-Tyr(TBU)-allyl ester HCl, methyl (2R)-2-amino-3-(3-chloro-4,5-dimethoxyphenyl) propanoate, methyl (2R)-2-amino-3-(2-chloro-3-hydroxy-4-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(4-[(2-chloro-6-fluorophenyl) methoxy] phenyl) propanoate, methyl (2R)-2-amino-3-(2-chloro-3,4-dimethoxyphenyl) propanoate, methyl (2R)-2-amino-3-(3-chloro-5-fluoro-4-hydroxyphenyl) propanoate, diethyl 2-(acetylamino)-2-(4-[(2-chloro-6-fluorobenzyl) oxy] benzyl malonate, methyl (2R)-2-amino-3-(3-chloro-4-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(3-chloro-4-hydroxy-5-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(2,6-dichloro-3-hydroxy-4-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(3-chloro-4-hydroxyphenyl) propanoate, H-DL-tyr-OMe HCl, H-3,5-diiodo-tyr-OMe HCl, H-D-3,5-diiodo-tyr-OMe HCl, H-D-tyr-OMe HCl, methyl D-tyrosinate hydrochloride, (2R)-2-amino-3-(4-hydroxyphenyl) propionic acid, (2R)-2-amino-3-(4-hydroxyphenyl) methyl ester hydrochloride, methyl (2R)-2-amino-3-(4-hydroxyphenyl) propanoate hydrochloride, methyl (2R)-2-azanyl-3-(4-hydroxyphenyl) propanoate hydrochloride, 3-chloro-L-tyrosine, 3-nitro-L-tyrosine, 3-nitro-L-tyrosine ethyl ester hydrochloride, DL-m-tyrosine, DL-o-tyrosine, Boc-Tyr(3,5-I 2 )—OSu, Fmoc-tyr(3-NO 2 )—OH, and α-methyl-DL-tyrosine;
b) melanin, a melanin promoter that is methoxsalen or melanotan II, or a combination of melanin, methoxsalen and melanotan II;
c) a p450 3A4 promoter that is 5,5-diphenylhydantoin, valproic acid, or carbamazepine; and
d) a leucine aminopeptidase inhibitor that is N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine, or rapamycin; and
wherein said cancer is metastatic cervical cancer, metastatic stomach cancer, metastatic liver cancer, metastatic testicular cancer, metastatic leukemia, metastatic appendix cancer, metastatic biliary cancer, metastatic germ cell tumor, metastatic neuroblastoma, metastatic tongue cancer, or metastatic urothelial cancer.
2. The method of claim 1 , wherein each of said tyrosine hydroxylase inhibitor, said melanin, melanin promoter, or combination of melanin, methoxsalen and melanotan II; said p450 3A4 promoter; and said leucine aminopeptidase inhibitor is administered to said patient within a 24 hour period.
3. The method of claim 1 , wherein each of said tyrosine hydroxylase inhibitor, said melanin, melanin promoter, or combination of melanin, methoxsalen and melanotan II; said p450 3A4 promoter; and said leucine aminopeptidase inhibitor is administered to said patient five days per week for six weeks.
4. The method of claim 1 , wherein said tyrosine hydroxylase inhibitor is α-methyl-DL-tyrosine.
5. The method of claim 1 , wherein said cancer is metastatic cervical cancer.
6. The method of claim 1 , wherein said cancer is metastatic stomach cancer.
7. The method of claim 1 , wherein said cancer is metastatic liver cancer.
8. The method of claim 1 , wherein said cancer is metastatic testicular cancer.
9. The method of claim 1 , wherein said cancer is metastatic leukemia.
10. The method of claim 1 , wherein said cancer is metastatic appendix cancer.
11. The method of claim 1 , wherein said cancer is metastatic biliary cancer.
12. The method of claim 1 , wherein said cancer is metastatic germ cell tumor.
13. The method of claim 1 , wherein said cancer is metastatic neuroblastoma.
14. The method of claim 1 , wherein said cancer is metastatic tongue cancer.
15. The method of claim 1 , wherein said cancer is metastatic urothelial cancer.